StromaBio

Executive Summary

StromaBio AB is a clinical-stage biopharmaceutical company based in Stockholm, Sweden, advancing allogeneic cell therapies derived from bone marrow mesenchymal stromal cells (MSCs). Founded in 2018, the company focuses on two high-value indications: Acute Respiratory Distress Syndrome (ARDS) and Alzheimer's Disease (AD). Its MSC platform leverages the immunomodulatory and regenerative properties of MSCs to address significant unmet medical needs. ARDS, often triggered by infections like COVID-19, lacks effective therapies, while Alzheimer's represents a massive global health challenge. StromaBio's preclinical data suggest potential disease-modifying benefits, positioning it for future clinical trials. The company operates in the rapidly growing cell therapy space but remains at an early stage with no disclosed funding or partnerships. Its success hinges on advancing its pipeline into human trials and securing capital for clinical development.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase 1 trial for MSC therapy in ARDS30% success
• Q3 2026Preclinical data publication or presentation for Alzheimer's disease program50% success
• Q2 2027Partnership or licensing deal for MSC platform20% success